Key result
Guideline-directed medical therapies curb cardiovascular remodeling by targeting organelle stress and inflammasome signaling.
Why the study?
Metabolic dysfunction and chronic inflammation are tightly interconnected drivers of cardiovascular remodeling, motivating a synthesis of the key immunometabolic mechanisms underlying atherosclerosis, myocardial ischemia-reperfusion injury, heart failure, and diabetic cardiomyopathy.
This review synthesizes how interconnected organelle stress responses, inflammasome signaling, and immune-cell metabolic reprogramming drive cardiovascular remodeling and highlights how cardiometabolic and anti-inflammatory therapies target these pathways.
Answers are grounded in this paper and cite their sources.
Interconnected metabolic-inflammatory drivers of remodeling merit targeted investigation; leaves open clinical translation of pathway-specific therapies.
Metabolic dysfunction and chronic inflammation are tightly interconnected drivers of cardiovascular remodeling. Lipid overload, hyperglycemia, insulin resistance, mitochondrial stress and gut-derived metabolites activate inflammatory pathways such as TLR4–NF-κB, JNK/mTORC1, cGAS–STING and the NLRP3 inflammasome. In turn, inflammatory mediators impair substrate utilization, mitochondrial homeostasis and insulin signaling, thereby promoting endothelial dysfunction, immune-cell metabolic reprogramming, fibroblast activation and progressive cardiac injury. This review summarizes key immunometabolic mechanisms underlying atherosclerosis, myocardial ischemia–reperfusion injury, heart failure and diabetic cardiomyopathy, with particular emphasis on interconnected mitochondrial, endoplasmic-reticulum and lysosomal stress responses, immune-cell metabolic reprogramming, inflammasome and cGAS–STING signaling, and gut–heart communication. Single-cell and spatial omics are integrated as an evidence layer to resolve disease-associated cell states and inflammatory tissue niches. We further discuss how established therapies, including SGLT2 inhibitors, GLP-1 receptor agonists, statins and colchicine, as well as emerging approaches targeting inflammasome activation, mitochondrial dysfunction and immune-metabolic pathways, may modulate these cellular and molecular circuits and inform future biomarker-guided therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a review in Cardiovascular remodeling (atherosclerosis, myocardial ischemia-reperfusion injury, heart failure, and diabetic cardiomyopathy). Immunometabolic therapeutic targeting (SGLT2 inhibitors, GLP-1 receptor agonists, statins, colchicine, and emerging inflammasome/mitochondrial modulators) was evaluated on Cardiovascular remodeling and progressive cardiac injury. Immunometabolic circuits involving organelle stress and inflammasome signaling drive cardiovascular remodeling and can be modulated by SGLT2 inhibitors, GLP-1 receptor agonists, statins, and colchicine.
Synapse has enriched 10 related papers. Consider them for comparative context: